aspirin as nanomedicine
DESCRIPTION
A new advanced aspirin www.nanomeda.comTRANSCRIPT
ASPIRINHYBRIDFrom Nanos Group
A new approach for cancer prevention and controlAspirinPlus
Hybrid
Aspirin
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction Mewa Singh
Not just for pain ButMore……………………………………………..
Problem Therapeutic compounds, such as aspirin,
are most stable in a crystalline form, but can display poor aqueous solubility and slow dissolution rates. These properties
impart the tendency to reduce the bioavailability of the active pharmaceutical
ingredient (API), thereby slowing absorption.
A safe solution from Meda Biotech
We believe there isn't one way to beat cancer - there are hundreds. For nearly 7 years, we've been committed to finding the right combination for cancer prevention that is safe and effective and of low cost
At the same time, it should support patient with therapies to boost immune system, reduce pain and improve quality of life
OUR BELIEF
DualAction
1. A pharmaceutical composition for treatment of conditions in mammals which are responsive to COX-2 inhibition which comprises in combination an effective amount of a COX-2 inhibitor and low-dose aspirin, wherein said low-dose of aspirin is equivalent to less than 75 milligrams per day of aspirin, for simultaneous, sequential or separate use wherein said condition is selected from the group of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombic occlusion and reocclusion, transient ischemic attack, myocardial infarction and first or subsequent thrombic stroke.
Novartis patent
DualAction
Acetylsalicylic acid may just keep cancers away, or so suggests a report released in the U.K. medical journal Lancet on December 7, 2010. The researchers looked at a great deal of data to come to their conclusion, with Dr. Peter M. Rothwell and colleagues examining records from 25,570 patients who had taken part in eight trials (“Effect of Daily Aspirin on Long-term Risk of Death Due to Cancer.”)
Can Low-Dose Acetylsalicylic Acid Prevent Cancer? | Suite101.com http://www.suite101.com/news/more-benefit-from-daily-low-dose-aspirin-cancer-prevention-a317573#ixzz1v8Nw2ldT
ASPIRINHYBRID
Nanosgroup AspirinHybrid is one step ahead of this game plan
Rational
DualAction
"Aspirin - which deactivates an enzyme associated with inflammation - offers a plausible means of reducing the inflammation that is part of cancer progression," he wrote about study results. "Effects of aspirin were strongest for cancers of the gastrointestinal tract, where aspirin exerts its most direct effects. This study reaffirms a potential role for aspirin in both cancer prevention and treatment, and suggests new directions for anti-cancer drug development.
Read more at Suite101: Can Low-Dose Acetylsalicylic Acid Prevent Cancer? | Suite101.com http://www.suite101.com/news/more-benefit-from-daily-low-dose-aspirin-cancer-prevention-a317573#ixzz1v8QWf1Ix
ASPIRINHYBRIDRational
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction
Inflammation is believed to contribute to a variety of cancers. Long-term inflammation leads to abnormal cell growth, or dysplasia. Examples include inflammation from infection. HPV can lead to cervical cancer and Hepatitis B puts individuals at risk for liver cancer.http://digitaljournal.com/article/320418#ixzz1v8h3lpMY
ASPIRINHYBRIDRational
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction
The scientists who developed the new drug decided including NO and H2S probably had dual benefits, so they came up with the ‘NOSH aspirin’.
The combination of studies related to aspirin for stopping cancer makes the possibility of the hybrid, powerful, gastrointestinal protective aspirin for development as an anti-cancer drug intriguing.http://digitaljournal.com/article/320418#ixzz1v8hwNjSvhttp://digitaljournal.com/article/320418#ixzz1v8hFF3L0
ASPIRINHYBRIDRational
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction
Rituxan - $3 billion Avastin - $2.66 billion Herceptin - $1.66 billion Gleevec - $1.51 billion Eloxatin - $1.2 billion Alimta - $1.04 billion Erbitux - $703.3 million Velcade - $692.7 million Xeloda - $647.6 million Tarceva - $564.2 million
Drugs in use for treatment
None for prevention or controlDualAction
PROGRESS
Proof of concept>>>>>>>>>>Completed R&D>>>>>>>>>>>>>>>>>>Completed Pilot scale >>>>>>>>>>>>> Completed Lab. Testing>>>>>>>>>>>>>Completed Animal Studies>>>>>>>>>>>Ongoing
Manufacturing Process>Under development GMP product >>>>>>>>>>>>Needed Clinical-I
Bioequivalence>>>>>>>>>>> Needed
$1MInvested
With time
$3MNeeded
Exit-1st- $100M
Exit-2nd- $250M
DualAction
Milestones
Scale Manufacturing 1st year Animal efficacy: Drug Interactions IND (2014) Phase I (2015) Phase III (2016) License submission
(2017-18)
DualAction
Our hybrid is designed to control inflammation Water soluble Synergistic effect Potentiating each other Potential to surpass existing aspirin brands
ASPIRINHYBRID
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction
ASPIRINHYBRID
DualAction
ASPIRINHYBRID
Prostaglandin production is increased by VEGF-D+ which is produced by metastatic cancer cells. Increased prostaglandin leads to dilation of lymphatic vessels allowing cancer cells to spread. Aspirin prevents cancer by inhibiting prostaglandin production, narrowing lymphatic vessels, restricting spread of cancer.No matter how easy cancer treatment may become, it is preferable to
prevent cancerDualAction
ASPIRINHYBRID
Hybrid
Hybrid
Hybrid
No matter how easy cancer treatment may become, it is preferable to prevent cancer
DualAction
DualAction
Nanocarriers serve as ideal delivery solutions for combination therapy which is required for effectively treating MDR cancer. The benefits of nanocarriers include, (1) they can be engineered to achieve multiple effects using one system; (2) nanocarriers improve the therapeutic index of drugs and can alter the pharmacokinetic profile of agents; (3) they preferentially accumulate in the tumor environment thanks to the EPR effect and their capacity to be conjugated to targeting moieties; and (4) nanocarriers avoid drug efflux by preferentially localizing agents in the peri-nuclear region of a cell, away from membrane localized efflux pumps.
Facts
DualAction
No matter how easy cancer treatment may become, it is preferable to prevent
cancer
DualAction
Currently, intravenous aspirin is not approved for use in the United States. The poor solubility of aspirin in water and its rapid hydrolysis in the plasma to salicylic acid and acetic acid have limited its intravenous use.
Attempts have been made in the past to produce an aspirin product having an acceptable solubility, but none have proven to be totally satisfactory.
For example, the introduction of Bayer aspirin, as well as Disprin (distributed in the United Kingdom), into water results in the formation of a cloudy suspension indicative of incomplete dissolution in water. Aspro Clear (distributed in Australia and New Zealand and marketed throughout Europe) imparts a non-cloudy, snow globe effect in water for more than three minutes after the tablets have effervesced.
Our Hybrid is unique and works much better and faster
Available Brands
DualAction
Nano Aspirin Delivery
DualAction
Aspirin crystals
Aspirin nano
Aspirin Hybrid Water Soluble
ARACHIDONIC ACID
Cox-ICox-II
ASCURINPROSTAGLANDINS
INFLAMMATION
ARACHIDONIC ACID
Cox-ICox-II
ASPIRINPROSTAGLANDINS
INFLAMMATIONDual
Action
IL6
DualAction